These protocols, however, involved a combination of immunoadsorption, therapeutic plasma exchange (TPE), intravenous immunoglobulin, immunosuppression with cyclophosphamide and corticosteroids, and FVIII administration.[12] The rationale for using TPE in AHA is the same as its use in thrombotic thrombocytopenic purpura (TTP). The gene discussed is F8; the disease is thrombotic thrombocytopenic purpura.